Sichenzia Ross Ference LLP Represents Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) in Offering of $1.2 Million American Depositary Shares
Press Release – New York, NY – May 23, 2019 – Sichenzia Ross Ference LLP announced today that it represented Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company, in a registered direct offering of American Depositary Shares (“ADSs”) and warrants to purchase ADSs. The Company received gross proceeds of approximately $1,200,000.
The Sichenzia Ross Ference LLP team was led by Partners Darrin Ocasio and Avital Perlman, Of Counsel Jeff Cahlon and Associate Grant Levine.
- Sichenzia Ross Ference LLP Represents BriaCell Therapeutics Corp. in Nasdaq listing and $25 Million Public Offering - February 26, 2021
- Sichenzia Ross Ference LLP Represents AmpliTech Group, Inc. in Nasdaq Uplisting and $11 Million Upsized Public Offering - February 25, 2021
- Sichenzia Ross Ference LLP Represents CloudCommerce, Inc. in $10.0 Million Registered Direct Offering - February 23, 2021